Blinded sample size reestimation in non-inferiority trials with binary endpoints
From MaRDI portal
Publication:5122986
Recommendations
- Sample size calculation and blinded sample size recalculation in clinical trials where the treatment effect is measured by the relative risk
- Including long- and short-term data in blinded sample size recalculation for binary endpoints
- Robustness of sample size re-estimation with interim binary data for double-blind clinical trials
- Blinded sample size re-estimation in clinical trials comparing several treatments
- Blinded sample size recalculation for normally distributed outcomes using long- and short-term data
Cited in
(11)- Sample size calculation and blinded sample size recalculation in clinical trials where the treatment effect is measured by the relative risk
- Sample size re-estimation: nonparametric approach
- Score confidence intervals and sample sizes for stratified comparisons of binomial proportions
- Including long- and short-term data in blinded sample size recalculation for binary endpoints
- Corrigendum to: Robustness of sample size re-estimation with interim binary data for double-blind clinical trials.
- Robustness of sample size re-estimation with interim binary data for double-blind clinical trials
- Sample size determination and re-estimation for matched pair designs with multiple binary endpoints
- Blinded sample size re-estimation with unequal variances and center effects in clinical trials
- Estimation of Treatment Difference and Standard Deviation with Blinded Data in Clinical Trials
- Blinded sample size re-estimation in clinical trials comparing several treatments
- Blinded versus unblinded estimation of a correlation coefficient to inform interim design adaptations
This page was built for publication: Blinded sample size reestimation in non-inferiority trials with binary endpoints
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5122986)
